Latest news with #SYK
Yahoo
02-08-2025
- Business
- Yahoo
Stryker (SYK) Reports Q2 Earnings: What Key Metrics Have to Say
For the quarter ended June 2025, Stryker (SYK) reported revenue of $6.02 billion, up 11.1% over the same period last year. EPS came in at $3.13, compared to $2.81 in the year-ago quarter. The reported revenue represents a surprise of +1.09% over the Zacks Consensus Estimate of $5.96 billion. With the consensus EPS estimate being $3.06, the EPS surprise was +2.29%. While investors scrutinize revenue and earnings changes year-over-year and how they compare with Wall Street expectations to determine their next move, some key metrics always offer a more accurate picture of a company's financial health. As these metrics influence top- and bottom-line performance, comparing them to the year-ago numbers and what analysts estimated helps investors project a stock's price performance more accurately. Here is how Stryker performed in the just reported quarter in terms of the metrics most widely monitored and projected by Wall Street analysts: Net Sales by Geography- Orthopaedics- Hips- United States: $283 million versus $279.15 million estimated by three analysts on average. Compared to the year-ago quarter, this number represents a +8.4% change. Net Sales by Geography- Orthopaedics- Knees- United States: $460 million compared to the $462.74 million average estimate based on three analysts. The reported number represents a change of +6.2% year over year. Net Sales by Geography- Orthopaedics- Hips- International: $183 million versus the three-analyst average estimate of $181.41 million. The reported number represents a year-over-year change of +9.6%. Net Sales by Geography- Orthopaedics- International: $675 million compared to the $739.65 million average estimate based on three analysts. The reported number represents a change of +0.2% year over year. Net Sales by Geography- Orthopaedics: $2.25 billion versus the six-analyst average estimate of $2.29 billion. The reported number represents a year-over-year change of -2.3%. Net Sales by Business- MedSurg and Neurotechnology: $3.77 billion compared to the $3.68 billion average estimate based on six analysts. The reported number represents a change of +21% year over year. Net Sales by Geography- Orthopaedics- Knees: $640 million versus $641.42 million estimated by four analysts on average. Compared to the year-ago quarter, this number represents a +6.3% change. Net Sales by Business- MedSurg and Neurotechnology- Medical: $990 million versus the four-analyst average estimate of $985.69 million. The reported number represents a year-over-year change of +9%. Net Sales by Business- MedSurg and Neurotechnology- Endoscopy: $899 million compared to the $835.42 million average estimate based on four analysts. The reported number represents a change of +17.1% year over year. Net Sales by Geography- Orthopaedics- Hips: $466 million versus $457.77 million estimated by four analysts on average. Compared to the year-ago quarter, this number represents a +8.9% change. Net Sales by Geography- Orthopaedics- Other: $183 million versus the four-analyst average estimate of $194.65 million. The reported number represents a year-over-year change of +34.6%. Net Sales by Geography- Orthopaedics- Trauma and Extremities: $957 million compared to the $916.05 million average estimate based on four analysts. The reported number represents a change of +15% year over year. View all Key Company Metrics for Stryker here>>> Shares of Stryker have returned -0.7% over the past month versus the Zacks S&P 500 composite's +2.3% change. The stock currently has a Zacks Rank #3 (Hold), indicating that it could perform in line with the broader market in the near term. Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Stryker Corporation (SYK) : Free Stock Analysis Report This article originally published on Zacks Investment Research ( Zacks Investment Research
Business Insider
17-07-2025
- Business
- Business Insider
RBC Capital Sticks to Their Buy Rating for Stryker (SYK)
In a report released on July 15, Shagun Singh Chadha from RBC Capital maintained a Buy rating on Stryker, with a price target of $435.00. The company's shares closed yesterday at $390.87. Elevate Your Investing Strategy: Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence. Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week. Singh Chadha covers the Healthcare sector, focusing on stocks such as Johnson & Johnson, Medtronic, and Boston Scientific. According to TipRanks, Singh Chadha has an average return of -1.0% and a 47.96% success rate on recommended stocks. Stryker has an analyst consensus of Strong Buy, with a price target consensus of $435.94, which is an 11.53% upside from current levels. In a report released yesterday, Bank of America Securities also maintained a Buy rating on the stock with a $450.00 price target. SYK market cap is currently $149.6B and has a P/E ratio of 52.83. Based on the recent corporate insider activity of 63 insiders, corporate insider sentiment is negative on the stock. This means that over the past quarter there has been an increase of insiders selling their shares of SYK in relation to earlier this year. Most recently, in May 2025, William E. Berry, the VP & CAO of SYK sold 1,241.00 shares for a total of $482,190.55.
Business Insider
17-07-2025
- Business
- Business Insider
Bank of America Securities Sticks to Their Buy Rating for Stryker (SYK)
In a report released yesterday, Travis Steed from Bank of America Securities maintained a Buy rating on Stryker, with a price target of $450.00. The company's shares closed yesterday at $390.87. Elevate Your Investing Strategy: Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence. Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week. According to TipRanks, Steed is a 4-star analyst with an average return of 6.3% and a 60.78% success rate. Steed covers the Healthcare sector, focusing on stocks such as Boston Scientific, Zimmer Biomet Holdings, and Becton Dickinson. Currently, the analyst consensus on Stryker is a Strong Buy with an average price target of $435.94, an 11.53% upside from current levels. In a report released on July 14, BTIG also maintained a Buy rating on the stock with a $413.00 price target. SYK market cap is currently $149.6B and has a P/E ratio of 52.83. Based on the recent corporate insider activity of 63 insiders, corporate insider sentiment is negative on the stock. This means that over the past quarter there has been an increase of insiders selling their shares of SYK in relation to earlier this year. Most recently, in May 2025, William E. Berry, the VP & CAO of SYK sold 1,241.00 shares for a total of $482,190.55.
Business Insider
15-07-2025
- Business
- Business Insider
Stryker awarded $450M Defense Logistics Agency contract modification
Stryker (SYK) has been awarded a maximum $450M modification exercising the five-year option period of a five-year base contract with one five-year option period for patient monitoring and capital equipment. This is a fixed-price with economic-price-adjustment, indefinite-delivery/indefinite-quantity contract. The ordering period end date is July 16, 2030. Using customers are Army, Navy, Air Force, Marines Corps, and federal civilian agencies. Type of appropriation is fiscal 2025 through 2030 defense working capital funds. The contracting activity is the Defense Logistics Agency Troop Support. Elevate Your Investing Strategy: Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence. Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
Yahoo
10-07-2025
- Business
- Yahoo
What to Expect From Stryker's Next Quarterly Earnings Report
Portage, Michigan-based Stryker Corporation (SYK) operates as a medical technology company that develops, manufactures, and markets specialty surgical and medical products. Valued at $148.7 billion by market cap, the company's products include implants, surgical, neurologic, ear, nose and throat and interventional pain equipment, endoscopic, surgical navigation, digital imaging systems, as well as patient handling and emergency medical equipment. The Medtech giant is expected to announce its fiscal second-quarter earnings for 2025 after the market closes on Thursday, Jul. 31. Ahead of the event, analysts expect SYK to report a profit of $3.06 per share on a diluted basis, up 8.9% from $2.81 per share in the year-ago quarter. The company has consistently surpassed Wall Street's EPS estimates in its last four quarterly reports. This Underdog AI Stock Just Got a New Street-High Price Target Texas Just Passed Quantum Computing Legislation. How Should You Play IONQ Stock Here? 'The Most Patriotic Thing You Can Do Is Not Pay the IRS' Says Grant Cardone as OBBBA Signed into Law — Here's How Much You'll Save Tired of missing midday reversals? The FREE Barchart Brief newsletter keeps you in the know. Sign up now! For the full year, analysts expect SYK to report EPS of $13.35, up 9.5% from $12.19 in fiscal 2024. Its EPS is expected to rise 11% year over year to $14.82 in fiscal 2026. SYK stock has outperformed the S&P 500 Index's ($SPX) 12.3% gains over the past 52 weeks, with shares up 16.8% during this period. Similarly, it outperformed the Health Care Select Sector SPDR Fund's (XLV) 6.5% dip over the same time frame. SYK thrives on growing procedural volumes and strong capital product demand. On May 1, SYK reported its Q1 results, and its shares closed up more than 1% in the following trading session. Its adjusted EPS of $2.84 exceeded Wall Street expectations of $2.73. The company's revenue was $5.9 billion, exceeding Wall Street forecasts of $5.7 billion. SYK expects full-year adjusted EPS in the range of $13.20 to $13.45. Analysts' consensus opinion on SYK stock is bullish, with a 'Strong Buy' rating overall. Out of 28 analysts covering the stock, 19 advise a 'Strong Buy' rating, two suggest a 'Moderate Buy,' and seven give a 'Hold.' SYK's average analyst price target is $431.77, indicating a potential upside of 10.1% from the current levels. On the date of publication, Neha Panjwani did not have (either directly or indirectly) positions in any of the securities mentioned in this article. All information and data in this article is solely for informational purposes. This article was originally published on Sign in to access your portfolio
